Bogdan Knezevic
About Bogdan Knezevic
Bogdan Knezevic is the Co-Founder and CEO of Kaleidoscope.bio, where he integrates technology with scientific research. He has a strong background in neuroscience and big data, and has held various roles in research and advisory capacities across multiple institutions.
Work at Kaleidoscope Technologies, Inc
Bogdan Knezevic serves as the Co-Founder and CEO of Kaleidoscope.bio, a position he has held since 2021. Under his leadership, the company focuses on integrating with the modern research stack to support multidisciplinary teams. This role allows him to apply his expertise in neuroscience and big data to enhance collaboration and scalability in scientific research and development.
Previous Experience in Artificial Intelligence and Research
Before his current role, Knezevic worked as the Artificial Intelligence Lead at Creative Destruction Lab in Toronto from 2019 to 2020. He also served as a Scientific Researcher at the Hotchkiss Brain Institute from 2010 to 2015. Additionally, he held advisory roles at Rhodes Incubator from 2017 to 2020 and was the Head of Program at Entrepreneur First from 2020 to 2021, both in Toronto.
Educational Background in Neuroscience and Genomics
Knezevic earned his Doctor of Philosophy (Ph.D.) in Clinical Medicine with a focus on computational approaches to drug discovery from the University of Oxford, where he studied from 2015 to 2020. He also holds a Bachelor of Science (B.Sc.) with honors in Neuroscience from the University of Calgary, completed from 2009 to 2015.
Achievements as a Rhodes Scholar
Knezevic is recognized as a Rhodes Scholar, an honor that reflects his academic excellence and leadership potential. This prestigious scholarship allowed him to pursue advanced studies at the University of Oxford, contributing to his expertise in genomics and drug discovery.
Passion for Technology in Scientific Research
Knezevic is passionate about leveraging technology to address major global issues. He focuses on enhancing collaboration, reproducibility, and scalability in scientific research and development, aiming to drive innovation in various fields through the application of big data and genomics.